Last €99.60 EUR
Change Today +2.36 / 2.43%
Volume 500.0
BAYA On Other Exchanges
Symbol
Exchange
OTC US
Xetra
OTC US
BrsaItaliana
Xetra
Mexico
Continuous
As of 3:54 AM 08/19/14 All times are local (Market data is delayed by at least 15 minutes).

bayer ag-sponsored adr (BAYA) Snapshot

Open
€100.50
Previous Close
€97.24
Day High
€100.50
Day Low
€98.35
52 Week High
06/2/14 - €106.75
52 Week Low
10/7/13 - €80.50
Market Cap
82.4B
Average Volume 10 Days
245.8
EPS TTM
--
Shares Outstanding
826.9M
EX-Date
04/25/14
P/E TM
--
Dividend
€2.78
Dividend Yield
2.10%
Current Stock Chart for BAYER AG-SPONSORED ADR (BAYA)

bayer ag-sponsored adr (BAYA) Related Bloomberg News

View More Bloomberg News

bayer ag-sponsored adr (BAYA) Details

Bayer Aktiengesellschaft develops, produces, and markets health care and agricultural products, and high-tech polymer materials worldwide. The company operates through HealthCare, CropScience, and MaterialScience segments. The HealthCare segment offers prescription pharmaceuticals, such as contraceptives, hemophilia treatments, anticoagulants, and medicines to treat multiple sclerosis, cancer, hypertension, and infectious diseases; and consumer health products comprising over-the-counter medications, dermatology products, nutritional supplements, veterinary medicines, and animal grooming products. This segment also provides medical care products, including blood glucose monitoring devices, such as single-strip and multi-strip systems; USB meters that feature integrated diabetes management software and direct plug-in to computers; contrast agent injection systems for diagnostic and therapeutic medical procedures in computed tomography, magnetic resonance imaging, and molecular imaging; and mechanical systems for removing thrombi from blood vessels, as well as service products for its systems. The CropScience segment offers products for use in agriculture as insecticides, fungicides, and herbicides or seed treatments; seeds and plant traits; and various products for gardens, green industry, and nonagricultural pest control. The MaterialScience segment provides high-tech polymer materials in the areas of polyurethanes, polycarbonates, coating and adhesive raw materials, and functional films; and produces and markets inorganic basic chemicals. The company has a strategic alliance with OncoMed Pharmaceuticals, Inc. to develop drugs to target cancer stem cell therapeutics. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

115,487 Employees
Last Reported Date: 07/29/14
Founded in 1863

bayer ag-sponsored adr (BAYA) Top Compensated Officers

Chairman of Management Board and Chief Execut...
Total Annual Compensation: €2.9M
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €1.8M
Labor Director and Member of Management Board
Total Annual Compensation: €1.1M
Compensation as of Fiscal Year 2013.

bayer ag-sponsored adr (BAYA) Key Developments

Bayer AG Reports Earnings Results for the Second Quarter Ended June 2014; Revises Earnings Guidance for the Year 2014

Bayer AG reported earnings results for the second quarter ended June 2014. For the quarter, the company's net profit jumped to EUR 953 million, boosted by demand for new drug lines and fertilizers. Net sales totaling EUR 10.5 billion (USD 14.07 billion), up 0.9% year on year from the equivalent quarter in 2013 when sales totaled EUR 10.4 billion. Net income rose by 13.3% year on year, buoyed partly by strong sales of its pharmaceutical products. Earnings before interest and taxes (EBIT) were up by 14.5% EUR 1.47 billion. Adjusted EBITDA increased by 1% to EUR 2.2 billion in the second quarter. Core earnings per share amounted to EUR 1.53 and came in at prior level. Net cash flow increased by 4% to EUR 1.6 billion because fewer funds were tied up in working capital than in the prior year period. With capital expenditures of EUR 529 million, the operating free cash flow came in at EUR 1.1 billion. Net financial debt increased from EUR 9.1 billion at the end of March to EUR 9.9 billion at the end of Second Quarter because cash inflows from operating activities only partly offset the outflows for the dividend payment in April. For the year 2014, the company's adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) were now expected to fall by around EUR 550 million compared with the previous forecast of 450 million. It expects group sales, adjusted for currency and portfolio effects, to rise 6% instead of the previously forecast 5%. The company now expects sales for the year to total some EUR 19.5 billion, where the company had previously suggested sales could total between EUR 19.5 billion to EUR 20 billion. The company also expects the negative impact of currency fluctuations to have a 4% downward effect on sales, where it had previously expected this to be around 2%. has suggested that it expects its pharmaceuticals division to see sales growth of 10% this year, up from previous estimates of single-digit growth. The company has also suggested that it anticipates spending an additional EUR 500 million in research and development expenses this year to push forward new products.

Bayer AG, Q2 2014 Earnings Call, Jul 30, 2014

Bayer AG, Q2 2014 Earnings Call, Jul 30, 2014

Bayer to Close Darmstadt Polycarbonate Plant

Bayer is to close its plastic polycarbonate production facility in Darmstadt as a result of market overcapacity and weak demand. The closure will affect 90 employees at the Bayer MaterialScience (BMS) site, with European customers to be supplied from sites in Nera Montoro, Italy, and Tielt, Belgium. The decision to shutter the site follows a review of Bayer's global polycarbonate business, which concluded that customer demand is insufficient to absorb overcapacities exacerbated by the entrance of new competitors into the sector. The company decided that a consolidation of its European polycarbonates operations was necessary to remain competitive.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAYA:GR €99.60 EUR +2.36

BAYA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cie de St-Gobain €37.44 EUR +0.75
GlaxoSmithKline PLC 1,413 GBp +3.00
Pfizer Inc $28.94 USD +0.10
Sanofi €79.75 EUR +0.14
Unilever PLC 2,637 GBp +28.00
View Industry Companies
 

Industry Analysis

BAYA

Industry Average

Valuation BAYA Industry Range
Price/Earnings 22.1x
Price/Sales 1.9x
Price/Book 4.0x
Price/Cash Flow 22.1x
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAYER AG-SPONSORED ADR, please visit www.bayer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.